Triaziquone

Triaziquone
Clinical data
Other names
  • 2,3,5-Tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione
  • Tris(aziridinyl)-p-benzoquinone
ATC code
Identifiers
  • 2,3,5-tris(aziridin-1-yl)benzo-1,4-quinone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.000.629 Edit this at Wikidata
Chemical and physical data
FormulaC12H13N3O2
Molar mass231.255 g·mol−1
3D model (JSmol)
  • C1CN1C2=CC(=O)C(=C(C2=O)N3CC3)N4CC4
  • InChI=1S/C12H13N3O2/c16-9-7-8(13-1-2-13)12(17)11(15-5-6-15)10(9)14-3-4-14/h7H,1-6H2 ☒N
  • Key:PXSOHRWMIRDKMP-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Triaziquone is a drug used in chemotherapy.

It is aziridinylbenzoquinone-based, and may have potential antineoplastic activity. [1]

It is an alkylating agent. It can react with DNA to form intrastrand crosslinks. It is a member of aziridines as well. [2]

References

  1. ^ PubChem. "Triaziquone". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-10.
  2. ^ Huang CH, Kuo HS, Liu JW, Lin YL (June 2009). "Synthesis and antitumor evaluation of novel bis-triaziquone derivatives". Molecules (Basel, Switzerland). 14 (7): 2306–16. doi:10.3390/molecules14072306. PMC 6255275. PMID 19633605.



Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.